Tenaya Therapeutics (Tenaya Therapeutics) 5-Year Yield-on-Cost % : 0.00 (As of May. 26, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Tenaya Therapeutics 5-Year Yield-on-Cost %?

Tenaya Therapeutics's yield on cost for the quarter that ended in Mar. 2024 was 0.00.

The historical rank and industry rank for Tenaya Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:

TNYA's 5-Year Yield-on-Cost % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.8
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Tenaya Therapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Tenaya Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tenaya Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Tenaya Therapeutics's 5-Year Yield-on-Cost % falls into.

Tenaya Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Tenaya Therapeutics is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

Tenaya Therapeutics (NAS:TNYA) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Tenaya Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Tenaya Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tenaya Therapeutics (Tenaya Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenaya Therapeutics Inc (NAS:TNYA) » Definitions » 5-Year Yield-on-Cost %

Comparable Companies

Traded in Other Exchanges

N/A

Address

171 Oyster Point Boulevard, Suite 500, South San Francisco, CA, USA, 94080

Website

https://www.tenayatherapeutics.com

Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.

Executives

Timothy Hoey	officer: Chief Scientific Officer	C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, 5TH FLR., SOUTH SAN FRANCISCO CA 94080
Leone D Patterson	officer: Chief Fin and Bus. Officer
Whittemore Tingley	officer: Chief Medical Officer	C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Faraz Ali	director, officer: Chief Executive Officer	C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BLVD., 5TH FLR., SOUTH SAN FRANCISCO Z4 94080
David V Goeddel	director, 10 percent owner	C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii Gp, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Amy L. Burroughs	director	TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Column Group Iii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Opportunity Iii Gp, Lp	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Tcg Opportunity Iii Gp, Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Opportunity Iii, Lp	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Deepak Srivastava	director	C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Column Group Iii-a, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Eli Casdin	director	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc	director	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019